Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind Randomized, Placebo Controlled Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Intravenous Ganaxolone as Adjunctive Therapy to Treat Subjects With Status Epilepticus

NCT03350035 is registered in ClinicalTrials.gov with Marinus Pharmaceuticals as lead sponsor.

NCT NCT03350035
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03350035 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind Randomized, Placebo Controlled Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Intravenous Ganaxolone as Adjunctive Therapy to Treat Subjects With Status Epilepticus
Lead sponsor
Marinus Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
February 19, 2018
Completion date
September 18, 2019
Enrollment
17 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

convulsive status epilepticus, epilepsy, non convulsive status epilepticus, status epilepticus